<DOC>
	<DOCNO>NCT02330510</DOCNO>
	<brief_summary>The prevalence Alzheimer 's Disease ( AD ) stroke double decade 65 year old . Both major cause dementia , currently estimate affect 46 million people worldwide . The current cost globally $ 818 billion . Additionally , population study elders 65 year , `` covert '' cerebral small vessel disease appear MRI scan silent lacunar infarct 25 % Microbleeds 10 % , focal diffuse 'incidental ' white matter disease ( WMD ) 95 % . WMD extensive 20 % , clinical threshold effect around 10cc2 . Small vessel disease even common dementia , often coexist AD independently contribute cognitive decline progression dementia . Longitudinal image use cerebral amyloid label open new opportunity understand additive/interactive effect small vessel disease AD . The design study include recruitment two cohort , include Mild Cognitive Impairment ( MCI ) and/or early Alzheimer Disease subject memory clinic subject strokes/TIA stroke prevention clinic . Inclusion criterion include presence moderate/extensive white matter disease , eg . Fazekas score 2 ( confluent peri-ventricular hyperintensities ) Fazekas score 3 , determine previous MR CT , &gt; 60 year age , Mini-Mental Status Exam ( MMSE ) score ≥ 20 . Subjects undergo 3T structural MRI ( include T1 , PD/T2 , FLAIR , GRE , DTI , ASL , rest state fMRI ) , glucose PET , amyloid PET ( use AV-45 florbetapir ) neuropsychological testing , well blood sampling . Repeat MR PET/CT image neuropsychological testing conduct 24 month . The imaging portion design closely parallel Alzheimer 's Disease Neuroimaging Initiative ( ADNI ) order benefit availability cognitively normal control ( NC ) , MCI Alzheimer 's disease subject minimal WMD .</brief_summary>
	<brief_title>Amyloid Glucose PET Imaging Alzheimer Vascular Cognitive Impairment Patients With Significant White Matter Disease</brief_title>
	<detailed_description>This study multi-center trial conduct center across Canada approximately 150 patient enrol . Participants recruit stroke prevention ( N=75 ) memory clinic ( N=75 ) end March 31 , 2016 . For comparison , access publically-available data use similar protocol collect normal control ( N=250 ) , MCI ( N=250 early MCI , N=150 late MCI ) AD patient ( N=150 ) without significant white matter disease , participate Alzheimer 's Disease Neuroimaging Initiative ( ADNI-GO ADNI 2 , N=800 ) , choose representative sample comparison score ≤ 1 represent non-white matter disease group . Three image modality use participant . 3 Telsa MRI scan acquire , use ADNI base protocol , except addition PD/T2 interleved sequence . Participants also undergo 18-fluoro PET AVID-45 ligand 18-fluorodeoxyglucose PET use ADNI protocol . The primary objective characterize baseline 2-year follow-up patient significant Periventricular White Matter Hyperintensities ( pvWMH ) , present transient cerebrovascular event memory problem , pattern : 1 . Uptake amyloid Florbetapir F-18 PET/CT 2 . Glucose uptake 18F-FDG PET/CT 3 . Volumetric measure brain structure MRI image 4 . Performance standard neuropsychological assessment , activity daily live gait speed . Secondary objective : 1 . Compare relationship amyloid brain uptake , pvWMH volume , cognitive score patient significant pvWMH control group individual cognitively normal , MCI AD , mild pvWMH , identify ADNI database . 2 . Examine relationship amyloid uptake , ApoE e4 genotype , structural MRI volume patient high burden pvWMH . 3 . Evaluate utility baseline brain amyloid predict cognitive decline increase pvWMH volume 2 year follow . 4 . Evaluate safety single intravenous dose Florbetapir F 18 Injection ( 370 MBq +/- 10 % ) subject significant pvWMH .</detailed_description>
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Cognition Disorders</mesh_term>
	<mesh_term>Leukoencephalopathies</mesh_term>
	<criteria>Eligible subject must meet follow criterion enrol study : 1 . Patients early AD amnestic , non‐amnestic single multidomain MCI confluent pvWMH ; recruit memory clinic . Or Patients minor stroke ( e.g . subcortical lacunar infarct ≤1.5cm ) TIA confluent pvWMH ; recruit stroke prevention clinic . 2 . Age ≥ 60 3 . Patients provide write informed consent 4 . Patients great 8 year education 5 . Patients expect survival great 2 year 6 . Patients sufficient fluency French English cognitive test 7 . Patients MiniMental State Exam score ( MMSE ) ≥ 20 8 . Patients pvWMH score CT MRI ≥2 periventricular Fazekas scale 31 NOTE : Fazekas 2 patient include bilateral posterior anterior periventricular cap extend 10mm ventricle ( i.e . halfway surround white matter v extend surround white matter require Fazekas 3 ) 1 . Subject meet one follow criterion eligible study : 2 . Patients cortical nonlacunar infarct image 3 . Patients persist hemiparesis motor stroke , leg strength &lt; 4/5 Medical Research Council ( MRC ) scale ; significant cerebellar ataxia 4 . Patients contraindication 3T MRI 5 . Patients major psychiatric disorder precede 5 year 6 . History substance abuse within past 2 year 7 . Serious/chronic systemic neurological illness ( AD ) Parkinson 's disease , multiinfarct dementia , Huntington 's disease , normal pressure hydrocephalus , brain tumor , progressive supranuclear palsy , seizure disorder , subdural hematoma , multiple sclerosis , history significant head trauma follow persistent neurologic deficit know structural brain abnormality 8 . Pain sleep disorder could interfere test 9 . Claustrophobia 10 . Patients receive radiation therapy head neck another research study involve radiation 11 . Patients unable unwilling comply protocol requirement deem investigator unfit study .</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Alzheimer 's Disease</keyword>
	<keyword>White Matter Hyperintensities</keyword>
	<keyword>Vascular Cognitive Impairment</keyword>
	<keyword>Amyloid Imaging</keyword>
	<keyword>Transient Ischemic Attack</keyword>
</DOC>